Cardinal Health, Inc. (CAH) — ESG & Values Scores

Environment story

Cardinal Health discloses minimal environmental data in its 10-K filing. Scope 1, 2, and 3 emissions are not quantified or disclosed. No net-zero commitment with a defined target year is stated in available documents. The company reports capital expenditures for manufacturing and distribution infrastructure ($547M in FY2025, projected $600M in FY2026) but does not detail decarbonization components. No renewable energy percentage or direct sustainability report was provided in source materials. Environmental scoring is significantly constrained by absent emissions baselines, no disclosed net-zero target, and no greenwashing mitigation narrative. Company operates large distribution and manufacturing footprint with substantial logistics exposure, yet environmental risk management disclosures are minimal.

Criticisms on file

No disclosed emissions data or net-zero target; minimal environmental transparency in 10-K filing
Source: CAH_10k.txt - Management's Discussion and Analysis; Risk Factors section
Large opioid litigation legacy; company distributed opioid pharmaceuticals and faces ongoing settlement obligations ($4.9B accrued at June 30, 2025)
Source: CAH_10k.txt - Note 8: Litigation (recoveries)/charges, net; contractual obligations table

Disclosed initiatives

Capital Investment in Distribution Infrastructure

FY2025: $547M capex; FY2026 guidance $600M, primarily for manufacturing and distribution infrastructure projects and technology investments.

Supports operational modernization and potential efficiency gains, but specific decarbonization targets not disclosed.
Tariff Mitigation and Cost Reduction

Company has taken actions to reduce potential impact of U.S. tariffs on costs through alternative sourcing and price increases.

Supply chain resilience measure; environmental impact unclear.

Social story

Cardinal Health reports limited social metrics in disclosed documents. CEO-to-worker pay ratio is not explicitly disclosed; CEO base salary of $1.5M with target total compensation of $17.125M is documented, but median worker pay is absent from filing. Board and executive leadership diversity percentages are not quantified in source materials. The proxy statement indicates board refreshment and gender diversity (e.g., Michelle Brennan as Committee Chair, women on board including Patricia Hemingway Hall, Nancy Killefer, Sheri Edison, Christine Mundkur) but precise diversity percentages are not stated. No documented union-suppression activities or major strikes in past 24 months are mentioned. Supply-chain ethics, particularly pharmaceutical ingredient sourcing and MSO (management services organization) labor practices, are not audited in available filings. Employee turnover rates and workplace safety metrics are undisclosed. Company has active union-related presence through Red Oak Sourcing joint venture with CVS Health but labor relations stance is neutral/undisclosed.

Criticisms on file

CEO-to-median-worker pay ratio not disclosed; cannot assess compliance with social equity thresholds
Source: CAH_proxy.txt - Executive Compensation section; base salary and target compensation disclosed but median employee pay absent
Workforce and leadership diversity percentages (women, underrepresented minorities) not quantified in proxy or 10-K
Source: CAH_proxy.txt - Board composition narrative; EEO-1 data or formal diversity metrics not provided
Employee turnover rate and workplace safety metrics undisclosed
Source: CAH_10k.txt and CAH_proxy.txt - Human capital disclosures minimal; no OSHA or safety reporting

Disclosed initiatives

Board Refreshment and Diversity

In March 2025, appointed Robert Musslewhite (healthcare technology/analytics) and Sudhakar Ramakrishna (cybersecurity/IT) to Board. Board includes multiple women directors (Michelle Brennan, Patricia Hemingway Hall, Nancy Killefer, Sheri Edison, Christine Mundkur). Michelle Brennan appointed Chair of Governance and Sustainability Committee; Dave Evans appointed Chair of Audit Committee.

Enhanced board governance and skill diversity; specific female/underrepresented minority percentages not disclosed.
Executive Compensation: Named Executive Officer Pay Structure

CEO Jason Hollar: base salary $1.5M, target total compensation $17.125M. CFO Aaron Alt: base salary $875K, target $5.6875M. All NEOs have annual incentive targets (100-175% of base) and long-term incentive grants. Base salary adjustments approved to move compensation closer to Comparator Group median.

Compensation aligned to market; CEO-to-median-worker ratio not disclosed, limiting social equity assessment.
Human Capital Management Oversight

Human Resources and Compensation Committee oversees human capital management strategies, policies, and compensation-related risks.

Formal governance structure in place; specific outcomes and metrics not disclosed in proxy.
MSO Acquisitions and Physician Recruitment

Acquisitions of GIA (73% stake, $2.8B), Urology America ($360M), ION ($1.1B), and ADS ($1.1B) with focus on recruiting and retaining local providers and supporting practice management.

Investment in physician-led networks and specialty practices; labor retention challenges in healthcare service model not audited.

Governance story

Cardinal Health demonstrates structured governance with a 12-member Board, majority independent (11 of 12 independent; Jason Hollar is CEO/insider). Board independence exceeds 90%, well above the 75% threshold. Share structure is single-class common equity with no dual-class voting; all shareholders have equal voting rights. Board composition includes financial expertise (Akhil Johri chairs Finance at Boeing; David Evans and Aaron Alt bring CFO/accounting backgrounds), healthcare expertise (Patricia Hemingway Hall ex-HCSC CEO), cybersecurity (Sudhakar Ramakrishna), operations, and international experience. Board committees are well-staffed and active (Audit: 6 meetings; Compensation: 6; Governance: 5; Risk Oversight: 5 in FY2025). Lobbying expenditures and political contributions are overseen by Governance and Sustainability Committee; no disclosed antitrust, consumer-safety, or financial-fraud regulatory proceedings are active in source materials. Company has paid substantial opioid litigation settlements ($4.9B accrued, $798M paid in FY2025) but these are historical and settled, not active enforcement actions. No evidence of shareholder proposal blocking or SEC consent decrees in current filings.

Criticisms on file

Opioid litigation settlement obligations: $4.9 billion accrued; ongoing annual payments through 2038
Source: CAH_10k.txt - Note 8: Litigation (recoveries)/charges, net; contractual obligations table shows $628M due in 2026, $523M in 2027-2028, $769M in 2029-2030, $2.9B thereafter
Lobbying expenditures and political contributions not quantified in proxy summary or 10-K; oversight is assigned to Governance Committee but specific amounts are not disclosed in source materials
Source: CAH_proxy.txt - Governance and Sustainability Committee charter mentions oversight of political/lobbying activities and annual policy review, but monetary values absent
No disclosed SEC consent decrees, active antitrust proceedings, or consumer-safety enforcement actions; company status appears compliant
Source: CAH_10k.txt - Risk Factors section; no active regulatory proceedings listed as material

Disclosed initiatives

Board Independence and Leadership Structure

11 of 12 directors independent. Gregory B. Kenny serves as independent Board Chair (non-executive); CEO Jason Hollar is sole insider director. Strong independent leadership with designated committee chairs: David Evans (Audit), Nancy Killefer (Compensation), Michelle Brennan (Governance and Sustainability), Sheri Edison (Risk Oversight).

Robust independent oversight; CEO/Board Chair separation ensures governance rigor.
Board Refreshment and Skill Alignment

Recent appointments of Robert Musslewhite (healthcare technology, analytics, CEO experience) and Sudhakar Ramakrishna (cybersecurity, enterprise software, CEO experience) in March 2025. Board skills matrix includes financial expertise, healthcare, operations, international markets, IT/cybersecurity, regulatory/legal/public policy.

Board composition closely aligned with strategic priorities and evolving risk landscape.
Governance and Sustainability Committee Oversight

Committee oversees sustainability activities, environmental/social/political risks, political contributions policy, lobbying activities, trade association payments, and Board succession planning. Annual review of political contributions policy conducted.

Formal governance structure for ESG and political risk; specific lobbying spend and political contribution amounts not disclosed in proxy summary.
Risk Oversight Committee

Committee oversees ethics and compliance program, healthcare fraud/abuse, antitrust, data privacy/security, anti-bribery/anti-corruption compliance, product quality, regulatory compliance.

Dedicated risk oversight distinct from audit function; compliance framework in place.
Executive Compensation Clawback Policy

Human Resources and Compensation Committee administers equity and incentive compensation plans and oversees compensation clawback policy terms.

Clawback mechanism in place; specific trigger conditions not detailed in proxy excerpt.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Cardinal Health, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Cardinal Health, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)